122 related articles for article (PubMed ID: 24614285)
1. Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines.
Katanasaka Y; Kodera Y; Yunokawa M; Kitamura Y; Tamura T; Koizumi F
Cancer Lett; 2014 Jun; 347(2):196-203. PubMed ID: 24614285
[TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
3. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
4. Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC.
Piao J; Chen L; Quan T; Li L; Quan C; Piao Y; Jin T; Lin Z
Oncotarget; 2016 Sep; 7(37):60169-60180. PubMed ID: 27507059
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Qu Y; Wu X; Yin Y; Yang Y; Ma D; Li H
J Exp Clin Cancer Res; 2014 Jun; 33(1):52. PubMed ID: 24939055
[TBL] [Abstract][Full Text] [Related]
6. Blockage of Stat3 enhances the sensitivity of NSCLC cells to PI3K/mTOR inhibition.
Jin HO; Lee YH; Park JA; Kim JH; Hong SE; Kim HA; Kim EK; Noh WC; Kim BH; Ye SK; Chang YH; Hong SI; Hong YJ; Park IC; Lee JK
Biochem Biophys Res Commun; 2014 Feb; 444(4):502-8. PubMed ID: 24472538
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Morgillo F; Sasso FC; Della Corte CM; Vitagliano D; D'Aiuto E; Troiani T; Martinelli E; De Vita F; Orditura M; De Palma R; Ciardiello F
Clin Cancer Res; 2013 Jul; 19(13):3508-19. PubMed ID: 23695170
[TBL] [Abstract][Full Text] [Related]
8. Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo.
Chang KY; Tsai SY; Wu CM; Yen CJ; Chuang BF; Chang JY
Clin Cancer Res; 2011 Nov; 17(22):7116-26. PubMed ID: 21976531
[TBL] [Abstract][Full Text] [Related]
9. Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
Stabile LP; Lyker JS; Gubish CT; Zhang W; Grandis JR; Siegfried JM
Cancer Res; 2005 Feb; 65(4):1459-70. PubMed ID: 15735034
[TBL] [Abstract][Full Text] [Related]
10. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
11. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
12. The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor.
Sano T; Takeuchi S; Nakagawa T; Ishikawa D; Nanjo S; Yamada T; Nakamura T; Matsumoto K; Yano S
Int J Cancer; 2013 Jul; 133(2):505-13. PubMed ID: 23319394
[TBL] [Abstract][Full Text] [Related]
13. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
Xia A; Li H; Li R; Lu L; Wu X
Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
[TBL] [Abstract][Full Text] [Related]
14. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
15. Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Zheng R; Jiang H; Li J; Liu X; Xu H
Curr Cancer Drug Targets; 2017; 17(4):376-385. PubMed ID: 28093061
[TBL] [Abstract][Full Text] [Related]
16. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S
Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474
[TBL] [Abstract][Full Text] [Related]
17. Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
Han SY; Zhao MB; Zhuang GB; Li PP
Lung Cancer; 2012 Jan; 75(1):30-7. PubMed ID: 21757251
[TBL] [Abstract][Full Text] [Related]
18. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
[TBL] [Abstract][Full Text] [Related]
19. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Janmaat ML; Kruyt FA; Rodriguez JA; Giaccone G
Clin Cancer Res; 2003 Jun; 9(6):2316-26. PubMed ID: 12796401
[TBL] [Abstract][Full Text] [Related]
20. Synergistic antitumor activity of sorafenib in combination with epidermal growth factor receptor inhibitors in colorectal and lung cancer cells.
Martinelli E; Troiani T; Morgillo F; Rodolico G; Vitagliano D; Morelli MP; Tuccillo C; Vecchione L; Capasso A; Orditura M; De Vita F; Eckhardt SG; Santoro M; Berrino L; Ciardiello F
Clin Cancer Res; 2010 Oct; 16(20):4990-5001. PubMed ID: 20810384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
